Rage fusion proteins and methods of use
US8877192B2 · kind B2 · utility
4Cited by
46References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 3, 2011 |
| Grant date | Nov 4, 2014 |
| Priority date | — |
| Expiry date | Jul 3, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.